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Comparative Effectiveness of Peripheral Vascular
Intervention Versus Surgical Bypass for Critical Limb
Ischemia in the Vascular Study Group of Greater
New York
Andrew J. Meltzer, Art Sedrakyan, Abby Isaacs, Peter H.
Connolly, Darren B. Schneider. Vascular Surgery, Weill
Cornell Medical College, New York, NY
Objectives: The purpose of this study is to compare
the effectiveness of peripheral vascular intervention (PVI)
vs surgical bypass grafts (BPG) for critical limb ischemia
(CLI) in the Vascular Study Group of Greater New York
(VSGGNY).
Methods: Patients undergoing BPG or PVI for CLI at
VSGGNY centers (2011-2013) were included. Using the
Society for Vascular Surgery Objective Performance Goals
(OPGs) for CLI, the safety and effectiveness of PVI and
BPG were initially directly compared. Propensity score
(PS) matching enabled risk-adjusted comparisons of PVI
vs BPG.
Results: A total of 414 patients (268 PVI, 146 BPG)
were treated for tissue loss (69%) or rest pain (31%). Pa-
tients undergoing PVI were more likely to have tissue
loss (74.6% vs 57.5%; P < .001) and comorbidities,
including diabetes (69.3% vs 57.5%; P ¼ .02), heart fail-
ure (22% vs 13.7%; P ¼ .04), and severe renal disease
(13.1% vs 4.1%; P ¼ .004). There were no signiﬁcant dif-
ferences across a panel of safety OPGs. At 1 year, direct
comparison of cohorts suggested superior effectiveness
with BPG: freedom from reintervention, amputation, or
restenosis (90.4% vs 81.7%; P ¼ .02) and freedom from
reintervention or amputation (92.5% vs 85.8%, P ¼
.045). After PS matching, PVI was associated with
increased freedom from major adverse limb events and
postoperative death at 1 year (95.6% vs 88.5%; P < .05;
Table).
Conclusions: By unadjusted comparison, early rein-
tervention and restenosis are more prevalent with PVI.
However, risk-adjusted comparison underscores the safety
and effectiveness of PVI in the treatment of CLI.Table. Vascular Study Group of Greater New York (VSGGNY
Outcome Metric
Unmatched coh
PVI BPG
(n ¼ 268) (n ¼ 14
% (CI) % (CI)
Amputationa 97.0 (95.0-99.1) 97.9 (95
Reintervention, amputation, or restenosisa 81.7 (77.1-86.3) 90.4 (85
Reintervention or amputationa 85.8 (81.6-90.0) 92.5 (88
Major adverse limb events + post-op deatha 89.6 (85.9-93.2) 90.4 (85
Amputation-free survival 87.7 (83.8-91.6) 91.1 (86
Overall survival 90.3 (86.8-93/8) 93.2 (89
a Reported as freedom from event.Author Disclosures: P. H. Connolly: Nothing to
disclose; A. Isaacs: Nothing to disclose; A. J. Meltzer:
Nothing to disclose;D. B. Schneider: Nothing to disclose;
A. Sedrakyan: Nothing to disclose.RR23.
Impact of Including Socioeconomic Status on Hospital
Proﬁling of Readmissions After Lower Extremity
Revascularization
Andrew A. Gonzalez2, Amir A. Ghaferi1. 1Section of
Vascular Surgery, University of Michigan, Ann Arbor,
Mich; 2University of Illinois Hospital & Health Sciences
System, Chicago, Ill
Objectives: Medicare’s Hospital Readmissions Reduc-
tion Program (HRRP) will require public reporting of
postsurgical readmission rates and ﬁnancial penalties for
high readmitting hospitals. Concerned with creating a dou-
ble standard for hospitals treating a high percentage of
indigent patients, Medicare elected to exclude socioeco-
nomic status (SES) from its risk-adjustment model. How-
ever, recent evidence suggests that hospitals caring for a
disproportionate share of low SES patients are more likely
to be penalized for excess readmissions. We sought to
investigate the effect of including SES on penalties and
reporting of hospital readmission rates following lower ex-
tremity revascularization procedures.
Methods: We used national Medicare data on 507,256
patients undergoing lower extremity arterial bypass, angio-
plasty, or stent placement between 2005 and 2009 to
generate risk-standardized 30-day readmission rates (RSRR).
We included only hospitals treating all strata of SES. Our
initial logistic regression model included age, sex, comorbid-
ities, and procedure type. We created a second model that
added SES as a three-level variable (low, medium, high).
Next, we tested whether including SES changed the propor-
tion of hospitals penalized under the HRRP, or penalty size.
Results: Our study population comprised 1909 hospi-
tals with an overall RSRR of 14.0% 6 1.6%. There was no
difference in the proportion of hospitals penalized after
adjusting for SES (56.5% vs 56.4%, P ¼ .885). However,
58% of institutions would receive lower penalties. Further,
hospitals treating a greater proportion of low-SES patients
more commonly received reduced penalties after adjustment
(odds ratio, 3.33; 95% conﬁdence interval, 2.42-4.60).) 12-month unadjusted and adjusted outcomes
orts Propensity-matched cohorts
P
PVI BPG
P
6) (n ¼ 113) (n ¼ 113)
% (CI) % (CI)
.6-100.0) .574 99.1 (95.2-100.0) 98.2 (93.8-99.8) .561
.6-95.2) .019 84.1 (76-90.3) 89.4 (82.2-94.4) .239
.2-96.7) .045 88.5 (81.1-93.7) 91.2 (84.3-95.7) .509
.6-95.2) .782 95.6 (90.0-98.5) 88.5 (81.1-93.7) .049
.5-95.7) .292 95.6 (90.0-98.5) 90.3 (83.2-95.0) .120
.1-97.2) .325 96.5 (91.2-99.0) 92.0 (85.4-96.3) .153
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Volume 59, Number 6S Abstracts 105SConclusions: Including SES in risk-adjustment for
readmissions after lower extremity revascularization would
impact the size of ﬁnancial penalties for low-SES serving
hospitals. This may have signiﬁcant implications for future
quality improvement initiatives at these institutions.
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Long-Term Beneﬁt of Open Renal Revascularization
for Stent Failure
Shaun M. Gifford, Thomas C. Bower, Audra A. Duncan,
Manju Kalra, Gustavo S. Oderich, Mark D. Fleming,
Randall R. DeMartino, Peter Gloviczki. Vascular Surgery,
Mayo Clinic, Rochester, Minn
Objectives: To determine long-term outcomes of pa-
tients needing open renal revascularization (ORR) for stent
failure.
Methods: Retrospective review was conducted of
consecutive patients operated on for renal stent failure
from 1998 to 2013. End points were hypertension, renal
function response, primary patency, reintervention, and
overall and hemodialysis (HD)-free survival.
Results: Of 878 ORR during this time, 37 patients
(70% female; mean age, 63 6 10 years) had 41 arteries
reconstructed for stent failure. Chronic kidney disease
(CKD) was stage 2 in 8%, stage 3 in 70%, stage 4 in
19%, and stage 5 in 3%. Reconstructions (bypass 84%)
were unilateral in 27 (mean glomerular ﬁltration rate
[GFR], 39.9 mL) and bilateral in 10 (mean GFR 47.1
mL). Twelve had ORR of a solitary kidney (mean GFR,
34.1 mL). Three procedure-related deaths occurred at
48, 65, and 210 days due to major adverse events. Over-
all, ﬁve patients needed HD (mean preoperative GFR
35.8 mL vs 43.7 mL in those without HD; P ¼ .29),
and three were permanent (8%). Over a mean follow-up
of 39 months (range, 2-112 months), mean systolic blood
pressure decreased from 153.9 to 134.3 mm Hg (P ¼
NS), and there was a signiﬁcant decrease in BP medica-
tions (2.98 before, 2.47 after; P ¼ .042). There was no
change in serum creatinine (1.54 mg/dL before; 1.62
mg/dL after), GFR (43.9 mL before; 45.8 mL after), kid-
ney length (10.6 cm before; 11.0 cm after), or CKD stage
(3.1 before and after). Two bypass grafts occluded, one at
5 days and the other at 18 months. One of these patients
needed HD, but both eventuated in renal transplant at 8
and 34 months, respectively. Three other grafts needed
four endovascular interventions for stenosis at 5, 13, 16,
and 17 months after operation. Primary patency was
82% at 5 years. Overall and HD-free survival was 85% at
5 years.
Conclusions: ORR for stent failure can be done safely,
is durable, requires few late interventions, and has excellent
freedom from HD. Patients may gain some improvement
in hypertension but have little change in renal function.
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Current Status of Symptomatic Nonatherosclerotic
Mesenteric Vascular Disease
Gregory J. Landry1, Alla Yarmosh1, Bhavesh Shukla1, Amir
F. Azarbal2, Timothy K. Liem1, Erica Mitchell1, Robert
McLafferty2, Gregory L. Moneta1. 1Oregon Health &
Science University, Portland, Ore; 2Portland VA Medical
Center, Portland, Ore
Objectives: To examine the epidemiology, treatment,
and outcomes of acute symptomatic nonatherosclerotic
mesenteric vascular disease (SNMVD) in a tertiary vascular
practice.
Methods: SNMVD was reviewed over a 6-year period
(2006-2012). Categories included embolism (EM), dissec-
tion (DI), and aneurysm (AN). Asymptomatic patients and
those with associated aortic pathology were excluded. Pre-
sentation, demographics, treatment, and outcomes were
recorded. Groups were compared with c2 and one-way
analysis of variance.
Results: Forty-six patients presented with SNMVD
(EM: 20, AN: 15, DI: 11). Age differed at presentation
(EM: 66.3 6 14.6, AN: 62.4 6 10.3, DI: 54.6 6 8.7
years; P < .05). Pain was the most frequent symptom
(EM: 100%, AN: 93%, DI: 91%; P ¼NS), with diarrhea be-
ing more frequent in EM (EM: 30%, AN: 7%, DI: 0%;
P < .05). EMs were more likely to affect the superior
mesenteric artery (SMA; EM: 80%, AN: 20%, DI: 45%; P
¼ .002), DI the hepatic artery (EM: 20%, AN: 13%, DI:
55%; P < .05), and AN SMA branches (EM: 5%, AN:
47%, DI: 0%; P ¼ .001). Males were more frequently
affected (EM: 80%, AN: 60%, DI: 73%; P ¼ NS). EMs
were more likely to have arrhythmia (EM: 40%, AN: 7%,
DI: 0%; P ¼ .008), with no other differences in pre-event
comorbidities or medications. The most common treat-
ment was surgical in EM (EM: 85%, AN: 33%, DI: 9%; P
< .001), endovascular (coiling or stenting) in AN (EM:
5%, AN: 40%, DI: 9%;P < .02), and conservative in DI
(EM: 15%, AN: 33%, DI: 82%). In-hospital mortality was
infrequent (EM: 10%, AN: 7%, DI: 0%; P ¼ NS). Mean
hospital length of stay differed by mechanism (EM: 13.6
days, AN: 9.2 days, DI: 2.3 days; P ¼ .005), although there
was a trend for increased readmission for DI (EM: 10%,
AN: 7%, DI: 36%; P ¼ .08). Mean follow-up was 14
months with no difference in 1-year survival (EM: 79%,
AN: 93%, DI: 100%; P ¼ NS).
Conclusions: Although EMs are the most common
cause of SNMVD, DI and AN are also common, but
with signiﬁcant differences in age, anatomic distribution,
and methods of treatment. With appropriate treatment,
1-year survival is excellent in all groups.
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